To compare the efficacy and safety of bevacizumab (Avastin; F. Hoffmann-La Roche Ltd, Basel, Switzerland) versus ranibizumab (Lucentis; Novartis Pharma AG, Basel, Switzerland) for neovascular age-related macular degeneration (nAMD) after 2 years when using a treat-and-extend protocol.

To analyze visual acuity (VA) outcomes before and after preplanned treatment regimen change in the VIEW studies at week 52 (W52).

To summarize the relative effects of bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) and ranibizumab (Lucentis; Genentech, Inc.), using findings from a Cochrane Eyes and Vision Group systematic review.

Intraocular pressure (IOP) is a major risk factor, as well as the only modifiable risk factor, for glaucoma. Racial differences have been observed in IOP measurements with individuals of African descent experiencing the highest IOP when compared with other ethnic groups. The purpose of this study was to examine the relationship between genetic ancestry and IOP in Latinos.

Radial retinal folds (RFs) extend from the optic disc to the peripheral retina and generally develop in utero or during the neonatal period owing to severe contractive traction caused by fibrovascular tissues in the periphery.1,2 Although RFs resemble the stalk of persistent fetal vasculature, these disorders are considered to differ. Several diseases have been reported to cause RFs, including familial exudative vitreoretinopathy (FEVR), retinopathy of prematurity, Bloch–Sulzberger syndrome, Norrie disease, and congenital toxoplasmosis.

The purpose of this study was to classify combined persistent fetal vasculature (PFV) on the basis of the ultrasonographic and Doppler characteristics. The potential clinical significance for both surgery design and prognosis determination was discussed.